Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Shona Hendry,Roberto Salgado,Thomas Gevaert,Prudence A Russell,Tom John,Bibhusal Thapa,Michael Christie,Koen van de Vijver,M V Estrada,Paula I Gonzalez-Ericsson,Melinda Sanders,Benjamin Solomon,Cinzia Solinas,Gert G G M Van den Eynden,Yves Allory,Matthias Preusser,Johannes Hainfellner,Giancarlo Pruneri,Andrea Vingiani,Sandra Demaria,Fraser Symmans,Paolo Nuciforo,Laura Comerma,E A Thompson,Sunil Lakhani,Seong-Rim Kim,Stuart Schnitt,Cecile Colpaert,Christos Sotiriou,Stefan J Scherer,Michail Ignatiadis,Sunil Badve,Robert H Pierce,Giuseppe Viale,Nicolas Sirtaine,Frederique Penault-Llorca,Tomohagu Sugie,Susan Fineberg,Soonmyung Paik,Ashok Srinivasan,Andrea Richardson,Yihong Wang,Ewa Chmielik,Jane Brock,Douglas B Johnson,Justin Balko,Stephan Wienert,Veerle Bossuyt,Stefan Michiels,Nils Ternes,Nicole Burchardi,Stephen J Luen,Peter Savas,Frederick Klauschen,Peter H Watson,Brad H Nelson,Carmen Criscitiello,Sandra O'Toole,Denis Larsimont,Roland de Wind,Giuseppe Curigliano,Fabrice André,Magali Lacroix-Triki,Mark van de Vijver,Federico Rojo,Giuseppe Floris,Shahinaz Bedri,Joseph Sparano,David Rimm,Torsten Nielsen,Zuzana Kos,Stephen Hewitt,Baljit Singh,Gelareh Farshid,Sibylle Loibl,Kimberly H Allison,Nadine Tung,Sylvia Adams,Karen Willard-Gallo,Hugo M Horlings,Leena Gandhi,Andre Moreira,Fred Hirsch,Maria V Dieci,Maria Urbanowicz,Iva Brcic,Konstanty Korski,Fabien Gaire,Hartmut Koeppen,Amy Lo,Jennifer Giltnane,Marlon C Rebelatto,Keith E Steele,Jiping Zha,Kenneth Emancipator,Jonathan W Juco,Carsten Denkert,Jorge Reis-Filho,Sherene Loi,Stephen B Fox

DOI: https://doi.org/10.1097/PAP.0000000000000161

Abstract:Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.